This prospective registry study investigates the impact of new hormone replacement therapy (HRT) delivery methods, such as creams, gels, and sprays, on cardiovascular risk in postmenopausal women. Menopause-related estrogen deficiency leads to metabolic and vascular changes that increase atherosclerosis and cardiovascular events. This study hypothesizes that new HRT forms may reduce cardiovascular risk in high-risk women."
female sex
Age 45-75 years at enrollment
Perimenopausal or postmenopausal status documented according to prespecified clinical criteria
Increased cardiovascular risk, defined as SCORE > 5 % (age 45-69 years) or SCORE2-OP > 5 % (age > 70 years), or established disease
Age <45 years or > 75 years
Active malignancy at screening
Inability to provide written informed consent or to comply with study procedures
Severe renal impairment, defined as estimated glomerular filtrate rate <30 ml/min/1.73m2, or dialysis dependance
Study Population: Peri and postmenopausal women with cardiovascular disease or high risk for CVD with and without hormon replacement therapy
Case-control
Prospective
Not listed
MACCE
defined as death, cardiovascular death, myocardial infarction, stroke, Transient Ischemic Attack, revascularization
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
